In today’s recent session, 0.67 million shares of the Esperion Therapeutics Inc (NASDAQ:ESPR) have been traded, and its beta is 0.68. Most recently the company’s share price was $0.81, and it changed around $0.02 or 2.63% from the last close, which brings the market valuation of the company to $160.76M. ESPR at last check was trading at a discount to its 52-week high of $3.94, offering almost -386.42% off that amount. The share price’s 52-week low was $0.69, which indicates that the recent value has risen by an impressive 14.81% since then. We note from Esperion Therapeutics Inc’s average daily trading volume that its 10-day average is 6.53 million shares, with the 3-month average coming to 5.40 million.
Esperion Therapeutics Inc stock received a consensus recommendation rating of Overweight, based on a mean score of 1.88. If we narrow it down even further, the data shows that 0 out of 8 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 2 recommended ESPR as a Hold, whereas 2 deemed it a Buy, and 1 rated it as Underweight. Esperion Therapeutics Inc is expected to report earnings per share of -0.19 for the current quarter.
Esperion Therapeutics Inc (NASDAQ:ESPR) trade information
Instantly ESPR has been showing a green trend so far today with a performance of 2.63% on intraday trading today. The performance over the last five days has remained in the red territory. The rise to weekly highs of 0.9199 on recent trading dayincreased the stock’s daily price by 11.95%. The company’s shares are currently down -63.13% year-to-date, but still down -6.11% over the last five days. On the other hand, Esperion Therapeutics Inc (NASDAQ:ESPR) is -11.84% down in the 30-day period. We can see from the shorts that 29.86 million shares have been sold at a short interest cover period of 5.19 day(s).
The consensus price target as assigned by Wall Street analysts is $8, which translates to bulls needing to increase their stock price by 89.88% from its current value. Analyst projections state that ESPR is forecast to be at a low of $8 and a high of $8.
Esperion Therapeutics Inc (ESPR) estimates and forecasts
The year-over-year growth rate is expected to be 3.57%, up from the previous year.
Consensus estimates provided by 8 financial analysts predict the company will bring in an average of 62.55M in revenue for the current quarter. 8 analysts expect Esperion Therapeutics Inc to make 92.41M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 73.83M and 51.63M respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -15.28%. Forecasts for the next quarter put sales growth at 78.97%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 40.11%.
ESPR Dividends
Esperion Therapeutics Inc’s next quarterly earnings report is expected to be released on 2025-May-05.
Esperion Therapeutics Inc (NASDAQ:ESPR)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 0.51% of Esperion Therapeutics Inc shares, and 59.30% of them are in the hands of institutional investors. The stock currently has a share float of 59.60%. Esperion Therapeutics Inc stock is held by 223.0 institutions, with WASATCH ADVISORS LP being the largest institutional investor. By 2024-06-30, it held 8.9319% of the shares, which is about 16.86 million shares worth $37.44 million.
BLACKROCK INC., with 7.4068% or 13.98 million shares worth $31.04 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
WASATCH FUNDS TRUST-Wasatch Ultra Growth Fund and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund were the top two Mutual Funds as of Mar 31, 2025 . The former held 6.68 shares worth $5.36 million, making up 3.37% of all outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund held roughly 6.18 shares worth around $4.96 million, which represents about 3.12% of the total shares outstanding.
